Literature DB >> 26324768

Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.

Teresa Lozano1, Lorea Villanueva1, Maika Durántez1, Marta Gorraiz2, Marta Ruiz2, Virginia Belsúe1, José I Riezu-Boj2, Sandra Hervás-Stubbs2, Julen Oyarzábal3, Hozefa Bandukwala4, Ana R Lourenço5, Paul J Coffer5, Pablo Sarobe2, Jesús Prieto1, Noelia Casares6, Juan J Lasarte6.   

Abstract

Regulatory T cell (Treg) activity is modulated by a cooperative complex between the transcription factor NFAT and FOXP3, a lineage specification factor for Tregs. FOXP3/NFAT interaction is required to repress expression of IL-2, upregulate expression of the Treg markers CTLA4 and CD25, and confer suppressor function to Tregs. However, FOXP3 is expressed transiently in conventional CD4(+) T cells upon TCR stimulation and may lead to T cell hyporesponsiveness. We found that a short synthetic peptide able to inhibit FOXP3/NFAT interaction impaired suppressor activity of conventional Tregs in vitro. Specific inhibition of FOXP3/NFAT interaction with this inhibitory peptide revealed that FOXP3 downregulates NFAT-driven promoter activity of CD40L and IL-17. Inhibition of FOXP3/NFAT interaction upregulated CD40L expression on effector T cells and enhanced T cell proliferation and IL-2, IFN-γ, IL-6, or IL-17 production in response to TCR stimulation. The inhibitory peptide impaired effector T cell conversion into induced Tregs in the presence of TGF-β. Moreover, in vivo peptide administration showed antitumor efficacy in mice bearing Hepa129 or TC1 tumor cells when combined with sorafenib or with an antitumor vaccine, respectively. Our results suggest that inhibition of NFAT/FOXP3 interaction might improve antitumor immunotherapies.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26324768     DOI: 10.4049/jimmunol.1402997

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function.

Authors:  Katrina M Hawley; Rachel J Eclov; Mathew R Schnorenberg; Yu Tian; Rhea N Shah; Anika T Thomas-Toth; Marie Fefferman; Gregory H Bird; Loren D Walensky; Matthew V Tirrell; James L LaBelle
Journal:  Proc Natl Acad Sci U S A       Date:  2022-10-13       Impact factor: 12.779

Review 2.  Histone/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation.

Authors:  L Wang; U H Beier; T Akimova; S Dahiya; R Han; A Samanta; M H Levine; W W Hancock
Journal:  Am J Transplant       Date:  2018-04-21       Impact factor: 8.086

3.  B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.

Authors:  Li Li; Jun Zhang; Juan Chen; Zijun Y Xu-Monette; Yi Miao; Min Xiao; Ken H Young; Sa Wang; L Jeffrey Medeiros; Michael Wang; Richard J Ford; Lan V Pham
Journal:  Blood       Date:  2018-09-12       Impact factor: 22.113

Review 4.  Forkhead box transcription factors as context-dependent regulators of lymphocyte homeostasis.

Authors:  Dietmar M W Zaiss; Paul J Coffer
Journal:  Nat Rev Immunol       Date:  2018-11       Impact factor: 53.106

Review 5.  Peptides that immunoactivate the tumor microenvironment.

Authors:  Natsuki Furukawa; Aleksander S Popel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-01       Impact factor: 10.680

Review 6.  Aptamers: A New Technological Platform in Cancer Immunotherapy.

Authors:  Fernando Pastor
Journal:  Pharmaceuticals (Basel)       Date:  2016-10-24

Review 7.  NFAT control of immune function: New Frontiers for an Abiding Trooper.

Authors:  Martin Vaeth; Stefan Feske
Journal:  F1000Res       Date:  2018-03-02

8.  Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor.

Authors:  Teresa Lozano; Marta Gorraiz; Aritz Lasarte-Cía; Marta Ruiz; Obdulia Rabal; Julen Oyarzabal; Sandra Hervás-Stubbs; Diana Llopiz; Pablo Sarobe; Jesús Prieto; Noelia Casares; Juan José Lasarte
Journal:  Oncotarget       Date:  2017-05-13

Review 9.  Revisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases.

Authors:  Jae-Ung Lee; Li-Kyung Kim; Je-Min Choi
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

10.  Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms.

Authors:  Jon Celay; Teresa Lozano; Axel R Concepcion; Elena Beltrán; Francesc Rudilla; María José García-Barchino; Eloy F Robles; Obdulia Rabal; Irene de Miguel; Carlos Panizo; Noelia Casares; Julen Oyarzabal; Jesús Prieto; Juan F Medina; Juan José Lasarte; José Ángel Martínez-Climent
Journal:  Haematologica       Date:  2017-11-30       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.